Aerie Pharmaceuticals Logo

Aerie At-a-Glance

We are committed to building a major ophthalmic pharmaceutical company. Our pathway to global leadership in eye care is based on continuous scientific innovation, world-class clinical development, and company-wide operational excellence in the pursuit of novel treatments for diseases of the eye with significant unmet need.

Aerie Corporate Highlights

  • Aerie Pharmaceuticals, Inc. is a publicly-traded company (NASDAQ: AERI)
  • Offices
    • HQ – Durham, NC
    • Dublin, Ireland
    • Irvine, CA
    • Bedminster, NJ
    • Tokyo, Japan
    • Henley-on-Thames, United Kingdom
  • Manufacturing
    • Athlone, Ireland (cGMP sterile fill facility; online in 2020)
    • Durham, NC (cGMP PRINT® implant production laboratory)
  • Employees: Over 370

Aerie Product Portfolio

  • Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
    • U.S. FDA approval – March 12, 2019
    • U.S. commercial launch – May 1, 2019
  • Rhopressa® (netarsudil ophthalmic solution) 0.02%
    • U.S. FDA approval – December 18, 2017
    • U.S. commercial launch – April 30, 2018

Pipeline Activities

  • Rhopressa®
    • 24-hour IOP reduction
    • Normal tension glaucoma
    • Aqueous humor dynamics
    • Pseudoexfoliative glaucoma
    • Corneal healing
  • Globalization plan under way
    • Europe and Japan
  • Retina program
    • AR-13503 and AR-1105 implants
    • AR-1105 IND active; Phase 2 trial ongoing
    • AR-13503 IND active; first-in-human clinical study ongoing
  • Multi-kinase inhibitors for other ophthalmic diseases and conditions
  • Beyond ophthalmology
    • Potential for Aerie-owned molecules from our proprietary kinase-inhibitor library in other therapeutic areas
TOP